The Hindu·2 min read·medium
Alembic Pharma gets U.S. FDA nod for generic chronic constipation drug
T
The Hindu Bureau
✦AI Summary
Alembic Pharmaceuticals has received U.S. FDA approval for its generic version of the chronic constipation drug Prucalopride. The drug is a therapeutic equivalent to Takeda's Motegrity and targets a $100 million market.
Generic drugmaker Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application for Prucalopride Tablets, 1 mg and 2 mg, used to treat chronic idiopathic constipation (CIC).
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in